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Glycosphingolipids (GSLs) are present in all mammalian cell plasma membranes and intracellular membrane structures. They 
are especially concentrated in plasma membrane lipid domains that are specialized for cell signaling. Plasma membranes have 
typical structures called rafts and caveola domain structures, with large amounts of sphingolipids, cholesterol, and sphingomy-
elin. GSLs are usually observed in many organs ubiquitously. However, GSLs, including over 400 derivatives, participate in diverse 
cellular functions. Several studies indicate that GSLs might have an effect on signal transduction related to insulin receptors and 
epidermal growth factor receptors. GSLs may modulate immune responses by transmitting signals from the exterior to the inte-
rior of the cell. Guillain-Barré syndrome is one of the autoimmune disorders characterized by symmetrical weakness in the mus-
cles of the legs. The targets of the immune response are thought to be gangliosides, which are one group of GSLs. Other GSLs may 
serve as second messengers in several signaling pathways that are important to cell survival or programmed cell death. In the search 
for clear evidence that GSLs may play critical roles in various biological functions, many researchers have made genetically engi-
neered mice. Before the era of gene manipulation, spontaneous animal models or chemical-induced disease models were used.
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INTRODUCTION 
Glycosphingolipids (GSLs) are ubiquitous cell membrane 
components of eukaryotic cells [1,2]. They are amphipathic 
molecules consisting of a ceramide and sugar chains, includ-
ing one or more glucose, galactose, and sialic acid residues, as 
shown Fig. 1. The ceramide portion is hydrophobic, and the 
sugar portion is hydrophilic as shown Fig. 2. These molecules 
are embedded in the leaflet of the membrane, as shown Fig. 3. 
GSLs are also present in intracellular components such as the 
Golgi apparatus, nuclear membrane, and mitochondria. GSLs, 
along with the associated membrane components, circulate 
through these organelles. In the Golgi apparatus, GSLs are new-
ly synthesized by the addition of saccharides one by one. On 
the other hand, in lysosomes, GSLs are degraded by the remov-
al of saccharides one by one. These products are the result of 
enzyme reactions [3]. More than 400 species of GSLs possess-
ing different sugar structures have been reported, although 
only seven monosaccharides have mainly been found in verte-
brate GSLs. 
  Microdomains called lipid rafts are functional units in cell 
membranes [4,5]. Such microdomains in cell membranes con-
sisting of GSL-cholesterol, function as platforms for the attach-
ment of lipid-modified proteins, such as glycosylphosphati-
dylinositol (GPI)-anchored proteins [6]. These specialized 
membrane microdomains may organize the assembly of sig-
naling molecules, membrane protein trafficking, and regulate 
neurotransmission and receptor trafficking [6]. Rietveld and 
Simons [7] found lipid rafts in model membranes to be related 
to the immiscibility of ordered and disordered liquid phases. 
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The cause of this immiscibility is uncertain, but the immisci-
bility may have a constant effect in events such as phosphory-
lation of the signal transduction molecules. These events in-
clude phosphorylation by tyrosine kinases and/or serine/thre-
onine kinases. Lipid rafts have been found by researchers to be 
involved in many signal transduction processes, including T 
cell antigen receptor signaling [8], B cell antigen receptor sig-
naling [9], epidermal growth factor receptor signaling [10], and 
insulin receptor signaling [11,12]. 
Sphingomyelin
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Fig. 1.  The synthetic pathway from ceramide. Following the synthesis of glucosylceramide, sphingomyelin, galactosylceramide, 
ceramide-1-phosphate, and sphingosine-1-phosphate, the derivatives are synthesized by enzyme activities predominantly in the 
Golgi apparatus.
Fig. 2.  Illustration of a eukaryotic cell membrane. It composed 
of the lipid bilayer, consisting of hydrophobic tails and hydro-
philic heads. 
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Fig. 3.  Glycosphingolipids (GSLs), cholesterol, sphingomy-
elin, and glycoproteins present in the cell membrane. Some vi-
ruses and bacteria might catch and use these molecules as the 
entry gate into cells. Cell-cell interaction might also occur 
through these molecules.
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  In this review, I summarize our understanding of the role of 
GSLs on the insulin receptor abnormality as one of the patho-
physiology of diabetes, and rodent models for the research on 
insulin resistance. 
CHARACTERIZATION OF GSLS
GSLs in a subclass that contains sialic acid residues are known 
as gangliosides, and are abundantly present in the nervous sys-
tem. Other subclasses of GSLs such as the globo series and 
isoglobo series, are abundant in red blood cells and leukocytes, 
respectively. Neolacto series and asialo series are also known. 
The synthesis of many GSLs starts from ceramide. Glucosylce-
ramide (GlcCer) synthase, the first enzyme required for the 
synthesis of GSLs, is a transmembrane protein located in the 
endoplasmic reticulum (ER) with its C-terminal catalytic do-
main located in the cytoplasm [13]. Following the synthesis of 
glucosylceramide, lactosylceramide, which consists of ceramide, 
glucose, and galactose, is synthesized in the Golgi apparatus as 
a key molecule in this synthetic pathway. Through this mole-
cule, higher-order GSL structures are produced by a series of 
Golgi glycosyltransferases. As a regular pathway, GlcCer is 
synthesized on the cytosolic side and must translocate across 
to the Golgi lumen for LacCer synthesis. However, recent evi-
dence has shown that GlcCer destined for glycolipid synthesis 
follows a different pathway and is transported back into the 
ER via the late Golgi protein FAPP2 [14]. GSLs have been im-
plicated in many fundamental cellular processes, including 
cell growth, migration, differentiation, morphogenesis, early 
development, and functioning of the nervous system [15-20]. 
GSLs seem to construct plasma membrane microdomains, 
known as rafts and caveolae [21,22], which are rich in sphin-
golipids, cholesterol, and sphingomyelin. As for metabolism, 
Whitmore et al. [23] demonstrated significant cell-to-cell het-
erogeneity in the amounts of gangliosides and their metabo-
lites. GSL expression varies among and within cell populations, 
during cellular differentiation, and between normal cells and 
their transformed counterparts. For the regulation of GSL me-
tabolism, Memon et al. [24], have reported that endotoxins (li-
popolysaccharide, LPS) and cytokines enhance hepatic sphin-
golipid synthesis, increase the activity and mRNA levels of 
serine palmitoyltransferase, the first committed step in sphin-
golipid synthesis, and increase the content of sphingomyelin, 
ceramide, and GlcCer in circulating lipoproteins of Syrian 
hamsters. Tettamanti described the metabolic turnover or re-
cycling of GSLs in a review [25]. Briefly, the events to be con-
sidered are de novo biosynthesis, in situ chemical modifica-
tions at the plasma membrane level, direct recycling to the 
plasma membrane from early endosomes, sorting to the Golgi 
apparatus from endosomes with subsequent glycosylation, 
degradation at the lysosomal/late endosomal level, salvage 
pathways, and complete degradation to waste products. The 
half-lives of GSLs seems to range from 2 to 6.5 hours, to three 
days depending on the cells or tissues used. 
GSLS, DIABETES, AND INSULIN RESISTANCE
Insulin is an anabolic hormone with regard to carbohydrate 
and lipid metabolism. Insulin exerts its effects via the insulin 
receptor (IR), a transmembrane receptor tyrosine kinase with 
two α-subunits and two β-subunits [26]. The α-subunits con-
tain the insulin-binding sites. The β-subunits form transmem-
brane and intracellular parts of the receptor. Following insulin 
binding, the IR undergoes a conformational change that al-
lows trans phosphorylation of the catalytic sites on multiple 
tyrosine residues [27]. The most important sites for the action 
of insulin are the liver, adipose tissues, and muscles. The con-
centration of IR is high in these tissues, with more than 
200,000 receptors on adipocytes and hepatocytes [27]. On the 
other hand, insulin resistance is defined as the reduced ability 
of a cell to respond to physiological concentrations of insulin. 
As a result of insulin stimulation, insulin binds to the IR and 
induces autophosphorylation of tyrosine kinase under normal 
physiological conditions. Following autophosphorylation, at 
least two signaling cascades are known. In the first, Akt to-
gether with protein kinase C promotes translocation of the 
glucose transporter (GLUT-4) to the plasma membrane en-
abling the uptake of glucose in the bloodstream. In the second, 
the mitogen activated protein kinase cascade is initiated [28]. 
The PI(3)K/Akt signaling pathway is central to proper insulin 
signaling [29]. As for cholesterol, Simons and Toomre [30] 
had reported that cholesterol depletion inhibited raft-depen-
dent signaling. Therefore, cholesterol in the cell membrane 
seems to act as a positive effector for IR and IRS-1 phosphory-
lation. What then are the effects of IR and IRS-1 phosphoryla-
tion by GSLs, which are components of the cell membrane like 
cholesterol? Generally, GSLs may play a prominent role in cell 
signaling, acting as both first and second messengers in a vari-
ety of signaling and regulatory pathways [31]. Of all the sphin-
golipids, ceramide and sphingosine, together with their phos-312
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phorylated counterparts, have received the most attention 
with regard to bioactivity. As one of the structures that GSLs 
participate in, lipid rafts are required for effective PI(3)K/Akt 
signaling. Moreover, Vainio et al. [32] have provided evidence 
that the IR is recruited to detergent-resistant domains upon li-
gand binding and the clustering of GM2 ganglioside inhibits 
IR signaling, apparently by excluding the ligand-bound IR 
from these domains. GM2 ganglioside may be important for 
the dynamic recruitment of the ligand-bound IR into the raft. 
  Diabetes mellitus type 2, which is known as non insulin-de-
pendent diabetes mellitus or adult-onset diabetes, is a meta-
bolic disorder that is characterized by a high glucose level in 
the bloodstream, insulin resistance, and insulin deficiency. 
Type 2 diabetes is a lifestyle- and genetic-related disease. The 
importance of various factors in the onset and pathological 
symptoms of the disease has been emphasized. There are many 
drugs with different mechanisms of action for this disease. For 
example, sulfonylureas lower blood sugar by stimulating the 
pancreas to release more insulin. Biguanides improve insulin’s 
ability to move sugar into cells, especially into muscle cells. 
Thiazolidinediones improve insulin’s effectiveness in muscle 
and fat tissues. Alpha-glucosidase inhibitors block enzymes 
that help digest starches, slowing the rise in blood sugar. Di-
peptidyl peptidase IV inhibitors work to lower blood sugar in 
patients with type 2 diabetes by increasing insulin secretion 
from the pancreas and reducing sugar production. Studies have 
shown that some diabetes pills may help prevent diabetes and 
diabetes-related complications. On the hand, Ottenhoff et al. 
[33] reported that pharmacological inhibition of glucosylce-
ramide synthase enhanced insulin sensitivity. They developed 
a highly specific, small molecule inhibitor of glucosylceramide 
synthase, N-(5′-adamantane-1′-yl-methoxy)-pentyl-1-
deoxynojirimycin (AMP-DNM). AMP-DNM counteracts 
TNF induced abnormalities in GSL concentrations and con-
comitantly reverses abnormalities in insulin signal transduc-
tion. Due to the pharmacological actions mentioned above, 
AMP-DNM significantly reduces GSL but not ceramide, con-
centrations in various tissues in mice and rats. Treatment of 
ob/ob mice with AMP-DNM normalizes their elevated tissue 
glucosylceramide levels, markedly lowers circulating glucose 
levels, improves oral glucose tolerance, reduces glycated he-
moglobin, and improves insulin sensitivity in muscle and liver 
tissues. It is typically reported that the density of GSLs is close-
ly related to insulin sensitivity in vivo. D-threo-1-Phenyl-2-
decanoylamino-3-morpholino-1-propanol (D-PDMP) is a 
well-known inhibitor of UDP-glucose, which is the first step 
of GSL synthesis [34]. This inhibitor has long been employed 
to study the roles of GSLs. The inhibitor is transported to the 
ER and Golgi apparatus [35]. Following treatment with D-
PDMP, nearly all GSL production is dramatically reduced on 
the surfaces of cells. In some cell lines, exogenously added Lac-
Cer rescues blocking by D-PDMP.
ANIMAL MODELS OF INSULIN RESISTANCE
Rat models
Though many animal models of diabetes have been estab-
lished, it is impossible to completely reproduce the condition 
of human patients. However, the knowledge gained from mod-
el animals contributes to our understanding of genetic diseas-
es, the effects of drugs, elucidation of pathological conditions, 
prevention, and treatments. Diabetes is a result of the lack of 
insulin. Amongst rodents, high-calorie feeding can induce hy-
pertriglyceridemia, insulin resistance, and hypertension. 
Sprague-Dawley (SD) rats [36] and Wistar rats [37,38] are es-
tablished models of sucrose-induced insulin resistance and 
hypertriglyceridemia. There are also high-fat rat models. The 
Goto-Gakizaki (GK) rat was established by genetic segrega-
tion based on the glucose level as early as eight days after birth. 
In GK rats, blood glucose level after oral glucose administra-
tion is high, with a severe glucose tolerance abnormality. GK 
rats also have metabolic-endocrine abnormalities, such as hy-
perglycemia and insulin resistance. In the pancreas, islet de-
formation, secretion abnormality, and gradual b-cell loss were 
observed [39]. The diabetic Zuker fatty rat was established as a 
fatty model rat [40,41]. An abnormal gain of weight is observed 
three weeks after birth and the body weight increases with age. 
Obese Zucker rats have high levels of lipids in their blood and 
are resistant to insulin. The Otsuka Long Evans Tokushima 
fatty (OLETF) rat is a useful animal model of type II diabetes 
with obesity [42,43]. The OLETF rat presents clinically rele-
vant phenotypes of diabetes such as hyperinsulinemia, hyper-
glycemia, insulin resistance, hypertriglycemia, and mild obe-
sity. In vivo insulin-stimulated glucose uptake as measured with 
a euglycemic clamp was reduced 37% compared with that in 
non-diabetic control rats. Morphological studies on the OLETF 
rat pancreas showed enlarged multi-lobulated fibrotic islets, 
and hyper states of insulin production and secretion. The Wis-
ter fatty rat (fa/fa) was developed by taking the fatty gene from 
the Zucker rat and transferring it to the Wistar-Kyoto rat, which 313
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is less sensitive to insulin, and less tolerant to glucose, than 
lean Zucker rats. Wistar fatty rats also exhibit obesity, hyper-
phagia, hyperlipidemia, hyperinsulinemia, and peripheral in-
sulin resistance, similar to Zucker rats. The tolerance and in-
sulin response to oral glucose are decreased with advancing 
age in males. Hypertrophy of pancreatic islets and degranula-
tion of beta cells have also been observed. 
Mouse models 
In contrast to rats, mice are used less frequently as a model for 
sucrose/fructose-induced insulin resistance and hypertriglyc-
eridemia. The response to high fructose/sucrose diets is very 
strain-dependent in mice [44], and commonly used strains 
like C57Bl/6 either do not develop insulin resistance or only 
develop it slowly [45]. When C57Bl/6 mice were fed a high-
fructose diet for eight weeks, they developed increased mean 
arterial pressure, reduced glucose tolerance, and increased 
plasma cholesterol that was attributed to the activation of the 
sympathetic and angiotensin systems [46]. Like the high di-
etary fructose used for the induction of diabetes, fat-based di-
ets can induce diabetes and obesity [47]. The effects of fat and 
sucrose were compared separately and in combination in dia-
betes- and obesity-prone C57Bl/6J and diabetes- and obesity-
resistant A/J mice. After four months, the feed efficiency 
(weight gained divided by calories consumed), did not differ 
across diets in A/J mice. However, C57Bl/6J mice had signifi-
cantly increased feed efficiency for the fat-based diet. The KK 
mouse was established in 1962 [48]. It shows a striking intoler-
ance to glucose, hyperinsulinism, and obesity. Of particular 
interest is the development of mild to moderate glomerulo-
sclerosis in the prediabetic stage. Later in life, progression to 
severe glomerulosclerosis and attendant proteinuria are ob-
served [49]. The ob/ob mouse is a mutant strain that eats ex-
cessively and becomes obese. It is one of the typical animal 
models of type 2 diabetes. In adipose tissue, enlargement of 
cells and an increase of cell number were observed. Idenfica-
tion of a mutation in the ob gene led to the discovery of leptin, 
which is important for the control of food consumption. Since 
the ob/ob mouse cannot produce leptin, its food intake is un-
controlled [50]. A mouse similar to the ob/ob mouse, the db/
db mouse, was eatablished [51]. This mouse exhibits severe di-
abetes with longstanding hyperglycemia. Moreover, within six 
weeks of age, db/db mice develop significant obesity, fasting 
hyperglycemia, and hyperinsulinemia. The db/db mice have a 
prominent peak in the low density lipoprotein (LDL) range. 
Upon consumption of a 0.15% (wt/wt) cholesterol and 21% 
(wt/wt) fat “western” diet, db/db mice show elevated plasma 
cholesterol [52]. The non-obese diabetic (NOD) mouse was 
established in 1984. Diabetes develops in NOD mice as a result 
of insulitis, leukocytic infiltration of the pancreatic islets [53,54]. 
The incidences of spontaneous diabetes in the NOD mouse 
are 60% to 80% in females and 20% to 30% in males. The onset 
of diabetes also varies between males and females. The time 
difference of the onset may be attributed to the breeding envi-
ronment. For chemical induction of diabetes, the N-nitro de-
rivative of glucosamin (STZ) is used frequently. STZ is a glu-
cosamine-nitrosourea compound that is particularly toxic to 
the insulin-producing β-cells in the pancreas in mammals. 
Multiple small doses of STZ produce a delayed, progressive 
increase in plasma glucose in mice within 5 to 6 days after the 
injections. High dose injection of STZ results in acute hyper-
glycemia. Alloxan, a crystalline substance produced by oxida-
tion of uric acid and a toxic glucose analogue, selectively de-
stroys β-cells in the pancreas when administrated to laborato-
ry animals, including mice and rats [55]. This causes insulin-
dependent diabetes mellitus similar to type 1 diabetes in hu-
man patients. This most likely occurs because of selective up-
take of the compound due to its structual similarity to glucose, 
as well as the β-cell’s highly efficient uptake mechanism [56].
Gene-manipulated mouse models
Knockout mouse technology is a valuable research tool and 
contributes to the clarification of biological questions. Via dis-
ruption of a specific gene in the mouse and observation of dif-
ferences from normal behaviour or responses, researchers can 
infer its probable biological function. However, some limita-
tions exist. With knockout mice, it is often difficult to deter-
mine a gene’s function in relation to human diseases as the 
genes in mice may have different functions from the human 
genes. Investigators have established knockout mouse models 
for diabetes research. However mice carrying a targeted dis-
ruption of the diabetes-related gene might develop early onset 
diabetes and die perinatally. Detailed examination of the pan-
creas revealed proliferation arrest and cell death in pancreatic 
β-cells. As a consequence, it is likely that these cumulative ef-
fects cause diabetes. 
  Considering carbohydrate chains including GSLs, diabetic 
mice with P-selectin glycoprotein ligand-1 (PSGL-1) deficien-
cy show a protective phenotype against obesity-related insulin 
resistance [57]. PSGL-1 knockout mice fed a high-fat diet (HFD) 314
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show a remarkable reduction of macrophage accumulation 
and expression of pro-inflammatory genes. Moreover, adipo-
cyte hypertrophy, insulin resistance, lipid metabolism, and he-
patic fatty change were improved in PSGL-1 knockout mice 
compared with WT mice fed HFD. PSGL-1 is a crucial adhe-
sion molecule for the recruitment of monocytes into adipose 
tissues in obese mice. Several studies have reported that block-
ade of PSGL-1 reduces inflammatory reactions [58,59]. Mice 
with gene disruption of GM3 are viable without major abnor-
malities, but have heightened sensitivity to insulin [60]. The 
basis for the increased insulin sensitivity in mutant mice was 
found to be enhanced IR phosphorylation in skeletal muscle. 
Importantly, the absence of the ganglioside GM3 confers pro-
tection from HDF-induced insulin resistance to the knockout 
mice. Gganglioside GM3 is a negative regulator of insulin sig-
naling.
CONCLUSION 
In this review, I summarized the molecular-based diversity of 
GSLs. Microdomains, termed lipid rafts, which are special 
structures of cell membranes are made of GSLs and protein 
receptors. These specialized membrane microdomains may 
compartmentalize cellular processes and function for the as-
sembly of signaling molecules. Since many molecules, such as 
receptors and channels penetrate cell membranes, the positive 
or negative influence (e.g., regulation of signaling, internaliza-
tion, and trafficking) of the cell membrane, including GSLs and 
other components, such as cholesterol, and sphingomyelin, is 
not small. On the other hand, model animals including mice 
with gene disruption are used for diabetes research. They pro-
vide an essential research tool for academic institutions and 
commercial companies by enabling the rapid screening of 
novel compounds, and testing of new gene-based therapies for 
the treatment of diabetes and diabetes-related symptoms.
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